GW Pharmaceuticals

News

NICE recommends cannabinoid med for severe epilepsy

Global biopharma Jazz Pharmaceuticals’ Epidyolex/Epidiolex (cannabidiol), developed by GW Pharmaceuticals and now part of Jazz, has received

News

Jazz breaks ground on $100m UK plant for cannabinoid drugs

Jazz Pharma has started construction of a manufacturing facility in the UK that will be used to manufacture cannabinoid drugs from its recently

News

NICE backs NHS funding for two cannabis-based drugs for firs...

NICE has recommended two of GW Pharma's cannabis-based medicines, the first time that medicines derived from the plant have been recommended for NHS funding.

News

GW launches cannabis-based epilepsy drug in US

GW Pharmaceuticals is bullish about the company’s prospects following the launch of its cannabis-based medicine for a rare form of childhood epilepsy.

NICE recommends cannabinoid med for severe epilepsy

Jazz breaks ground on $100m UK plant for cannabinoid drugs

NICE backs NHS funding for two cannabis-based drugs for firs...

GW launches cannabis-based epilepsy drug in US

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

GW Pharmaceuticals

Editor's Picks